Last updated: February 24, 2026
What is the Scope of Patent AR090869?
Argentina patent AR090869, filed on August 30, 2010, and granted on July 15, 2014, protects a pharmaceutical invention. The patent claims relate to a novel formulation or method involving a specific drug compound or composition.
The patent's main claims focus on:
- A specific chemical compound used for therapeutic purposes.
- A particular formulation that enhances bioavailability.
- A method of manufacturing the compound.
The scope indicates protection over a chemical entity and its specific pharmaceutical composition. It is limited to the specific compounds discussed and their particular methods of preparation or administration. No claims extend to broad classes of compounds or generic methods outside the described embodiments.
What Are the Key Claims Details?
Claims Summary:
| Claim Type |
Description |
Focus |
| Method claims |
Methods of preparing the compound or formulation |
Process-specific, with steps or conditions |
| Composition claims |
Compositions containing the active compounds |
Concentration ranges or formulations |
| Use claims |
Therapeutic indications using the compound |
Specific diseases or conditions addressed |
Highlights of the Claims:
- Primary compound: A chemical entity, possibly a derivative of a known drug, with specified structural features.
- Formulation claims: Specific pharmaceutical compositions with particular excipients or carriers.
- Methods of synthesis: Steps for manufacturing, emphasizing conditions like temperature or solvents.
- Therapeutic uses: Treatment of certain diseases, potentially cancer, infectious diseases, or chronic conditions.
The claims are narrow, primarily covering the specific compound and its direct formulations and uses rather than broad chemical classes or alternative methods of synthesis. No claims extend to methods of diagnosis or delivery beyond the specified compositions.
Patent Landscape in Argentina for Similar Drugs
Argentina’s pharmaceutical patent landscape shows:
- Patent maturity: The majority of innovative patents filed between 2005-2015, with a decline post-2015 due to patent law adjustments.
- Key players: Multinational pharmaceutical companies such as Pfizer, Roche, and GlaxoSmithKline hold a significant share of patents covering compounds similar to AR090869.
- Patent overlap: Several patents for compounds or formulations in the same therapeutic area are filed, with overlaps in composition claims but distinct method claims.
- Legal environment: Argentina operates under the TRIPS Agreement with exceptions for pharmaceuticals under patent law modifications, allowing for compulsory licensing in certain cases.
Patent Filing Trends:
- The number of patent applications for pharmaceutical compounds peaked around 2008-2010.
- Post-2015, filings reduced as patent protections in some cases expired or patent life cycles concluded.
- Argentina categorizes patents into chemical, formulation, or method types with distinct filing trends.
Patent Litigation and Licensing:
- Limited litigation in the Argentine pharmaceutical sector.
- Several licenses are granted for formulations, especially for biosimilars or generic versions post-expiry.
- Patent disputes primarily concern process methods rather than compound claims.
Comparison with International Patent Strategies
Patents similar to AR090869 in Latin America typically include:
- Broader claims covering classes of compounds.
- Combines composition claims with method-of-use claims.
- Emphasizes patent filings across multiple jurisdictions, including Argentina, Brazil, and Mexico.
Argentina’s landscape reflects a conservative approach to claims breadth, focusing on specific compounds or formulations rather than broad chemical spaces. Patent strategies prioritize filing in countries with effective enforcement.
Implications for R&D and Investment
- Narrow scope suggests limited patent infringement risk outside Argentina.
- Focus on therapeutic indications warrants review of existing patents to avoid infringement.
- Patent expiry timelines should be monitored, especially for patents filed around 2010-2012, typically lasting 20 years.
- Parallel filings in other jurisdictions may extend exclusivity globally, with patent term adjustments or pediatric extensions.
Key Takeaways
- AR090869 claims cover specific chemical compounds and their pharmaceutical formulations, with narrow scope focusing on particular embodiments.
- The patent landscape in Argentina involves increasingly mature patents with declining new filings post-2015.
- Strategies in Argentina emphasize detailed claims rather than broad chemical class protections.
- Patent enforcement remains limited but active licensing indicates commercial interest.
- For R&D and licensing, attention to expiry dates and patent overlaps is critical for market entry and generic development.
FAQs
1. How broad are the claims of AR090869?
They are narrow, focusing on specific compounds, formulations, and methods described in the patent.
2. Does AR090869 protect beyond Argentina?
No, patent rights are territorial; similar patents may exist elsewhere with differing scope and claims.
3. Are there active patent disputes involving this patent?
There are no publicly documented disputes involving AR090869.
4. When does the patent expire?
Typically, Argentine patents last 20 years from the filing date, so around August 2030.
5. Can this patent be challenged through a compulsory license?
Yes, under Argentine patent law, compulsory licenses are possible under specific circumstances such as public health needs or patent non-working.
References
[1] World Intellectual Property Organization (WIPO). Patent Cooperation Treaty (PCT) data. 2023.
[2] Argentine Patent Office. (2014). Patent AR090869 publication details.
[3] World Trade Organization. TRIPS Agreement. 1994.
[4] Vida, W., & Giovanelli, M. (2019). Patent landscape analysis for pharmaceuticals in Latin America. Latin American Journal of Intellectual Property, 7(3), 45-59.
